Eric Johnson, MD
Hematology & Oncology · Salt Lake City, UTNPI 1649665399
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. BTG International Inc. accounts for 93.9% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $13,921, more than ten times the $60 reported in 2019.
Across 34 payments — averaging $434.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BTG International Inc.$14K
- Stryker$305
- Astellas Pharma US Inc$170
- Viiv Healthcare Company$132
- Sanofi$103
- Teva Pharmaceuticals USA, Inc.$48
- plus $148 from 6 others
What the payments were for
- Consulting fees$7,18049%
- Travel & lodging$6,28143%
- Food & beverage$1,1047%
- Education$1961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BTG International Inc. | 14 | $13,854 |
| Stryker | 1 | $305 |
| Astellas Pharma US Inc | 2 | $170 |
| Viiv Healthcare Company | 7 | $132 |
| Sanofi | 1 | $103 |
| Teva Pharmaceuticals USA, Inc. | 1 | $48 |
| AstraZeneca | 2 | $40 |
| GSK | 2 | $31 |
| Amgen | 1 | $24 |
| Krystal Biotech Inc | 1 | $23 |
| Sobi, Inc | 1 | $18 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ICONIX$305
How this compares
$14,761 in reported general payments places this provider in the 70th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 49 | $782,887 |
| RevlimidLenalidomide | 31 | $621,506 |
| ImbruvicaIbrutinib | 15 | $251,315 |
| BrukinsaZanubrutinib | 12 | $179,526 |
| LonsurfTrifluridine/Tipiracil Hcl | 13 | $173,967 |
| ZykadiaCeritinib | 13 | $167,400 |
| EliquisApixaban | 59 | $49,945 |
| Abiraterone Acetate | 29 | $14,485 |
| Anastrozole | 88 | $1,649 |
| Letrozole | 91 | $1,524 |
| Oxycodone Hcl | 52 | $759 |
| Dexamethasone | 43 | $746 |
| Prochlorperazine Maleate | 41 | $478 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 36 | $478 |
| Gabapentin | 29 | $453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $40 | $782,88749 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $48 | $42557 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in Salt Lake City
- Douglas SborovSalt Lake City$473K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Benjamin MaughanSalt Lake City$142K
- Schickwann TsaiSalt Lake City$137K
- Heloisa SoaresSalt Lake City$111K
- Daanish HodaSalt Lake City$80K
- Tsewang TashiSalt Lake City$69K
- Finn PetersenSalt Lake City$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.